+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Pharmacogenomics Market 2020-2030 by Service (Genotyping, SNP, Diagnostics), Technology (PCR, Microarray, Sequencing, Electrophoresis, MS), Application, End User, and Region: Trend Forecast and Growth Opportunity

  • ID: 5157165
  • Report
  • September 2020
  • Region: Global
  • 181 pages
  • GMD Research
1 of 4

Order now to receive an updated version of this report covering the impact of COVID-19.

Enquire Now

FEATURED COMPANIES

  • 23andMe, Inc.
  • Admera Health, LLC
  • Astra Zeneca PLC
  • Cancer Genetics, Inc.
  • Empire Genomics LLC
  • Genomic Health, Inc.
  • MORE
Global pharmacogenomics market will reach $12.83 billion by 2030, growing by 8.1% annually over 2020-2030 driven by increase in adoption of personalized medicine and surge in usage of pharmacogenomics for drug discovery and development amid COVID-19 pandemic.

Highlighted with 88 tables and 83 figures, this 181-page report “Global Pharmacogenomics Market 2020-2030 by Service (Genotyping, SNP, Diagnostics), Technology (PCR, Microarray, Sequencing, Electrophoresis, MS), Application, End User, and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global pharmacogenomics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.

In-depth qualitative analyses include identification and investigation of the following aspects:
  • Market Structure
  • Growth Drivers
  • Restraints and Challenges
  • Emerging Product Trends & Market Opportunities
  • Porter’s Five Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global pharmacogenomics market in every aspect of the classification from perspectives of Service, Technology, Application, End User, and Region.

Based on Service, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
  • Genotyping
  • SNP Identification
  • Diagnostics
  • Other Services
Based on Technology, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
  • Polymerase Chain Reaction (PCR)
  • Microarray
  • Sequencing
  • Electrophoresis
  • Mass Spectrometry
  • Other Technologies
Based on Application, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
  • Oncology
  • Infectious Diseases
  • Neurology/Psychiatry
  • Cardiovascular
  • Pain Management
  • Other Applications
Based on End User, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
  • Hospitals and Clinics
  • Pharmaceutical Companies
  • Research Institutes
Geographically, the following regions together with the listed national/local markets are fully investigated:
  • APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
  • Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)
  • North America (U.S., Canada, and Mexico)
  • South America (Brazil, Chile, Argentina, Rest of South America)
  • MEA (Saudi Arabia, UAE, South Africa)
For each aforementioned region and country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Service, Technology, and Application over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in global pharmacogenomics market are assayed quantitatively and qualitatively through a Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request):
  • 23andMe, Inc.
  • Abbott Laboratories
  • Admera Health, LLC
  • Agena Biosciences, Inc.
  • Astra Zeneca PLC
  • Bayer AG
  • Becton, Dickinson and Company
  • Cancer Genetics, Inc.
  • Dynamic DNA Laboratories
  • Empire Genomics LLC
  • F. Hoffmann-La Roche Ltd
  • geneOmbio Technologies Pvt Ltd.
  • Genomic Health, Inc.
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • Myriad Genetics Inc.
  • Oneome LLC
  • Opko Health, Inc.
  • Pathway Genomics Corporation
  • QIAGEN N.V.
  • Quest Diagnostics Incorporated
  • Teva Pharmaceuticals Industries Ltd.
  • Thermo Fisher Scientific Inc.
  • Transgenomic, Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 23andMe, Inc.
  • Admera Health, LLC
  • Astra Zeneca PLC
  • Cancer Genetics, Inc.
  • Empire Genomics LLC
  • Genomic Health, Inc.
  • MORE
1 Introduction
1.1 Industry Definition and Research Scope
1.1.1 Industry Definition
1.1.2 Research Scope
1.2 Research Methodology
1.2.1 Overview of Market Research Methodology
1.2.2 Market Assumption
1.2.3 Secondary Data
1.2.4 Primary Data
1.2.5 Data Filtration and Model Design
1.2.6 Market Size/Share Estimation
1.2.7 Research Limitations
1.3 Executive Summary

2 Market Overview and Dynamics
2.1 Market Size and Forecast
2.1.1 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Five Forces Analysis

3 Segmentation of Global Market by Service
3.1 Market Overview by Service
3.2 Genotyping
3.3 SNP Identification
3.4 Diagnostics
3.5 Other Services

4 Segmentation of Global Market by Technology
4.1 Market Overview by Technology
4.2 Polymerase Chain Reaction (PCR)
4.3 Microarray
4.4 Sequencing
4.5 Electrophoresis
4.6 Mass Spectrometry
4.7 Other Technologies

5 Segmentation of Global Market by Application
5.1 Market Overview by Application
5.2 Oncology
5.3 Infectious Diseases
5.4 Neurology/Psychiatry
5.5 Cardiovascular
5.6 Pain Management
5.7 Other Applications

6 Segmentation of Global Market by End User
6.1 Market Overview by End User
6.2 Hospitals and Clinics
6.3 Pharmaceutical Companies
6.4 Research Institutes

7 Segmentation of Global Market by Region
7.1 Geographic Market Overview 2019-2030
7.2 North America Market 2019-2030 by Country
7.2.1 Overview of North America Market
7.2.2 U.S.
7.2.3 Canada
7.2.4 Mexico
7.3 European Market 2019-2030 by Country
7.3.1 Overview of European Market
7.3.2 Germany
7.3.3 UK
7.3.4 France
7.3.5 Spain
7.3.6 Italy
7.3.7 Russia
7.3.8 Rest of European Market
7.4 Asia-Pacific Market 2019-2030 by Country
7.4.1 Overview of Asia-Pacific Market
7.4.2 Japan
7.4.3 China
7.4.4 Australia
7.4.5 India
7.4.6 South Korea
7.4.7 Rest of APAC Region
7.5 South America Market 2019-2030 by Country
7.5.1 Argentina
7.5.2 Brazil
7.5.3 Chile
7.5.4 Rest of South America Market
7.6 MEA Market 2019-2030 by Country
7.6.1 UAE
7.6.2 Saudi Arabia
7.6.3 South Africa
7.6.4 Other National Markets

8 Competitive Landscape
8.1 Overview of Key Vendors
8.2 New Product Launch, Partnership, Investment, and M&A
8.3 Company Profiles
  • 23andMe, Inc.
  • Abbott Laboratories
  • Admera Health, LLC
  • Agena Biosciences, Inc.
  • Astra Zeneca PLC
  • Bayer AG
  • Becton, Dickinson and Company
  • Cancer Genetics, Inc.
  • Dynamic DNA Laboratories
  • Empire Genomics LLC
  • F. Hoffmann-La Roche Ltd
  • geneOmbio Technologies Pvt Ltd.
  • Genomic Health, Inc.
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • Myriad Genetics Inc.
  • Oneome LLC
  • Opko Health, Inc.
  • Pathway Genomics Corporation
  • QIAGEN N.V.
  • Quest Diagnostics Incorporated
  • Teva Pharmaceuticals Industries Ltd.
  • Thermo Fisher Scientific Inc.
Transgenomic, Inc.

9 Investing in Global Market: Risk Assessment and Management
9.1 Risk Evaluation of Global Market
9.2 Critical Success Factors (CSFs)

List of Tables
Table 1. Snapshot of Global Pharmacogenomics Market, 2019-2030
Table 2. Web-based Resources of Pharmacogenomics
Table 3. Main Product Trends and Market Opportunities in Global Pharmacogenomics Market
Table 4. Global Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 5. Medicine/Gene Matching in Pharmacogenetic Testing
Table 6. Global Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 7. Global Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 8. Important Drug-Gene Pairs Relevant to Neurology and Psychiatry
Table 9. Global Pharmacogenomics Market by End User, 2019-2030, $ mn
Table 10. Global Pharmacogenomics Market by Region, 2019-2030, $ mn
Table 11. Total Health Expenditure per capita in PPP International U.S. Dollars by Country
Table 12. Leading National Pharmacogenomics Market, 2019 and 2030, $ mn
Table 13. North America Pharmacogenomics Market by Country, 2019-2030, $ mn
Table 14. U.S. Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 15. U.S. Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 16. U.S. Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 17. Canada Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 18. Canada Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 19. Canada Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 20. Mexico Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 21. Mexico Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 22. Mexico Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 23. Europe Pharmacogenomics Market by Country, 2019-2030, $ mn
Table 24. Germany Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 25. Germany Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 26. Germany Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 27. UK Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 28. UK Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 29. UK Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 30. France Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 31. France Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 32. France Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 33. Spain Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 34. Spain Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 35. Spain Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 36. Italy Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 37. Italy Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 38. Italy Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 39. Russia Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 40. Russia Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 41. Russia Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 42. Pharmacogenomics Market in Rest of Europe by Country, 2019-2030, $ mn
Table 43. APAC Pharmacogenomics Market by Country, 2019-2030, $ mn
Table 44. Japan Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 45. Japan Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 46. Japan Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 47. China Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 48. China Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 49. China Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 50. Australia Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 51. Australia Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 52. Australia Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 53. India Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 54. India Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 55. India Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 56. South Korea Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 57. South Korea Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 58. South Korea Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 59. Pharmacogenomics Market in Rest of APAC by Country, 2019-2030, $ mn
Table 60. South America Pharmacogenomics Market by Country, 2019-2030, $ mn
Table 61. Argentina Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 62. Argentina Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 63. Argentina Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 64. Brazil Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 65. Brazil Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 66. Brazil Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 67. Chile Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 68. Chile Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 69. Chile Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 70. MEA Pharmacogenomics Market by Country, 2019-2030, $ mn
Table 71. UAE Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 72. UAE Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 73. UAE Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 74. Saudi Arabia Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 75. Saudi Arabia Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 76. Saudi Arabia Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 77. South Africa Pharmacogenomics Market by Service, 2019-2030, $ mn
Table 78. South Africa Pharmacogenomics Market by Technology, 2019-2030, $ mn
Table 79. South Africa Pharmacogenomics Market by Application, 2019-2030, $ mn
Table 80. Product Approvals by Company, January 2016 – April 2019
Table 81. Breakdown of Global Market by Key Vendor, 2019, %
Table 82. 23andMe, Inc.: Company Snapshot
Table 83. 23andMe, Inc.: Business Segmentation
Table 84. 23andMe, Inc.: Product Portfolio
Table 85. 23andMe, Inc.: Revenue, 2016-2018, $ mn
Table 86. 23andMe, Inc.: Recent Developments
Table 87. Risk Evaluation for Investing in Global Market, 2019-2030
Table 88. Critical Success Factors and Key Takeaways

List of Figures
Figure 1. Research Method Flow Chart
Figure 2. Breakdown of Primary Research
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 4. Global Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030
Figure 5. Global Pharmacogenomics Market, 2019-2030, $ mn
Figure 6. An Overall Process of How Pharmacogenomics Functions in a Clinical Practice
Figure 7. Impact of COVID-19 on Business
Figure 8. Primary Drivers and Impact Factors of Global Pharmacogenomics Market
Figure 9. World Top 10 Causes of Deaths, 2016
Figure 10. Primary Restraints and Impact Factors of Global Pharmacogenomics Market
Figure 11. Consecutive Phases and Associated Challenges in Pharmacogenomics
Figure 12. Investment Opportunity Analysis
Figure 13. Porter’s Five Forces Analysis of Global Pharmacogenomics Market
Figure 14. Breakdown of Global Pharmacogenomics Market by Service, 2019-2030, % of Revenue
Figure 15. Global Addressable Market Cap in 2020-2030 by Service, Value ($ mn) and Share (%)
Figure 16. Global Pharmacogenomics Market: Genotyping, 2019-2030, $ mn
Figure 17. Global Pharmacogenomics Market: SNP Identification, 2019-2030, $ mn
Figure 18. Global Pharmacogenomics Market: Diagnostics, 2019-2030, $ mn
Figure 19. Global Pharmacogenomics Market: Other Services, 2019-2030, $ mn
Figure 20. Breakdown of Global Pharmacogenomics Market by Technology, 2019-2030, % of Sales Revenue
Figure 21. Global Addressable Market Cap in 2020-2030 by Technology, Value ($ mn) and Share (%)
Figure 22. Global Pharmacogenomics Market: Polymerase Chain Reaction (PCR), 2019-2030, $ mn
Figure 23. Global Pharmacogenomics Market: Microarray, 2019-2030, $ mn
Figure 24. Global Pharmacogenomics Market: Sequencing, 2019-2030, $ mn
Figure 25. Global Pharmacogenomics Market: Electrophoresis, 2019-2030, $ mn
Figure 26. Global Pharmacogenomics Market: Mass Spectrometry, 2019-2030, $ mn
Figure 27. Global Pharmacogenomics Market: Other Technologies, 2019-2030, $ mn
Figure 28. Breakdown of Global Pharmacogenomics Market by Application, 2019-2030, % of Sales Revenue
Figure 29. Global Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%)
Figure 30. Global Pharmacogenomics Market: Oncology, 2019-2030, $ mn
Figure 31. Global Pharmacogenomics Market: Infectious Diseases, 2019-2030, $ mn
Figure 32. Global Pharmacogenomics Market: Neurology/Psychiatry, 2019-2030, $ mn
Figure 33. Global Pharmacogenomics Market: Cardiovascular, 2019-2030, $ mn
Figure 34. Global Pharmacogenomics Market: Pain Management, 2019-2030, $ mn
Figure 35. Global Pharmacogenomics Market: Other Applications, 2019-2030, $ mn
Figure 36. Breakdown of Global Pharmacogenomics Market by End User, 2019-2030, % of Revenue
Figure 37. Global Addressable Market Cap in 2020-2030 by End User, Value ($ mn) and Share (%)
Figure 38. Global Pharmacogenomics Market: Hospitals and Clinics, 2019-2030, $ mn
Figure 39. Global Pharmacogenomics Market: Pharmaceutical Companies, 2019-2030, $ mn
Figure 40. Global Pharmacogenomics Market: Research Institutes, 2019-2030, $ mn
Figure 41. Global Market Snapshot by Region
Figure 42. Geographic Spread of Worldwide Pharmacogenomics Market, 2019-2030, % of Sales Revenue
Figure 43. Global Addressable Market Cap in 2020-2030 by Region, Value ($ mn) and Share (%)
Figure 44. Health Spending as a Share of GDP by Country, 2015 and 2030
Figure 45. North American Pharmacogenomics Market, 2019-2030, $ mn
Figure 46. Breakdown of North America Pharmacogenomics Market by Country, 2019 and 2030, % of Revenue
Figure 47. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%)
Figure 48. U.S. Pharmacogenomics Market, 2019-2030, $ mn
Figure 49. Canada Pharmacogenomics Market, 2019-2030, $ mn
Figure 50. Pharmacogenomics Market in Mexico, 2015-2030, $ mn
Figure 51. European Pharmacogenomics Market, 2019-2030, $ mn
Figure 52. Breakdown of European Pharmacogenomics Market by Country, 2019 and 2030, % of Revenue
Figure 53. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%)
Figure 54. Pharmacogenomics Market in Germany, 2019-2030, $ mn
Figure 55. Pharmacogenomics Market in UK, 2019-2030, $ mn
Figure 56. Pharmacogenomics Market in France, 2019-2030, $ mn
Figure 57. Pharmacogenomics Market in Spain, 2019-2030, $ mn
Figure 58. Pharmacogenomics Market in Italy, 2019-2030, $ mn
Figure 59. Pharmacogenomics Market in Russia, 2019-2030, $ mn
Figure 60. Pharmacogenomics Market in Rest of Europe, 2019-2030, $ mn
Figure 61. Asia-Pacific Pharmacogenomics Market, 2019-2030, $ mn
Figure 62. Breakdown of APAC Pharmacogenomics Market by Country, 2019 and 2030, % of Revenue
Figure 63. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%)
Figure 64. Pharmacogenomics Market in Japan, 2019-2030, $ mn
Figure 65. Pharmacogenomics Market in China, 2019-2030, $ mn
Figure 66. Pharmacogenomics Market in Australia, 2019-2030, $ mn
Figure 67. Pharmacogenomics Market in India, 2019-2030, $ mn
Figure 68. Pharmacogenomics Market in South Korea, 2019-2030, $ mn
Figure 69. Pharmacogenomics Market in Rest of APAC, 2019-2030, $ mn
Figure 70. South America Pharmacogenomics Market, 2019-2030, $ mn
Figure 71. Breakdown of South America Pharmacogenomics Market by Country, 2019 and 2030, % of Revenue
Figure 72. Contribution to South America 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%)
Figure 73. Pharmacogenomics Market in Argentina, 2019-2030, $ mn
Figure 74. Pharmacogenomics Market in Brazil, 2019-2030, $ mn
Figure 75. Pharmacogenomics Market in Chile, 2019-2030, $ mn
Figure 76. Pharmacogenomics Market in Rest of South America, 2019-2030, $ mn
Figure 77. Pharmacogenomics Market in Middle East and Africa (MEA), 2019-2030, $ mn
Figure 78. Breakdown of MEA Pharmacogenomics Market by Country, 2019 and 2030, % of Revenue
Figure 79. Contribution to MEA 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%)
Figure 80. Pharmacogenomics Market in UAE, 2019-2030, $ mn
Figure 81. Pharmacogenomics Market in Saudi Arabia, 2019-2030, $ mn
Figure 82. Pharmacogenomics Market in South Africa, 2019-2030, $ mn
Figure 83. Growth Stage of Global Pharmacogenomics Industry over the Forecast Period
Note: Product cover images may vary from those shown
3 of 4
  • 23andMe, Inc.
  • Abbott Laboratories
  • Admera Health, LLC
  • Agena Biosciences, Inc.
  • Astra Zeneca PLC
  • Bayer AG
  • Becton, Dickinson and Company
  • Cancer Genetics, Inc.
  • Dynamic DNA Laboratories
  • Empire Genomics LLC
  • F. Hoffmann-La Roche Ltd
  • geneOmbio Technologies Pvt Ltd.
  • Genomic Health, Inc.
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • Myriad Genetics Inc.
  • Oneome LLC
  • Opko Health, Inc.
  • Pathway Genomics Corporation
  • QIAGEN N.V.
  • Quest Diagnostics Incorporated
  • Teva Pharmaceuticals Industries Ltd.
  • Thermo Fisher Scientific Inc.
  • Transgenomic, Inc.
Note: Product cover images may vary from those shown
4 of 4

Loading
LOADING...

Adroll
adroll